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The CCR5 chemokine receptor is a promising target for
antiretroviral therapy because of its role as a coreceptor for
HIV entry and propagation of infection. Vicriviroc, a small
molecule CCR5 inhibitor being studied in clinical trials,
has shown potent in vitro activity against HIV (IC90<13
nM). In addition, the pharmaceutic and PK/PD properties
of vicriviroc appear to distinguish it from other com-
pounds in clinical development.
Vicriviroc is highly water-soluble and demonstrates oral
bioavailability of >89% in rats and monkeys. The com-
pound is modestly human plasma protein-bound (≈
84%) and widely distributed in the extra vascular space.
Absorption and exposure in humans are linear and dose-
proportional, with a terminal phase half-life >24 hours
supportive of once daily dosing. Variability in absorption
is modest (20–40%). Exposure to vicriviroc, a substrate
for CYP3A4, is "boosted" by CYP3A4 inhibition with
ritonavir (RTV), without being affected by other metabo-
lizing enzymes or pGp. Because of the high oral bioavail-
ability and highly predictable exposure, particularly when
boosted with as little as 100 mg RTV, potent HIV suppres-
sion of 1.5 log10 is anticipated with as little as 10 mg vic-
riviroc daily with RTV. Dosage adjustments are not
expected in combination regimens.
Vicriviroc shows particular promise as an HIV therapeutic
due to pharmaceutic, PK/PD properties that support its
potent activity and convenient once daily dosing.
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